不同浓度的富马毒素B1对肝癌细胞凋亡的影响

目的探讨不同浓度富马毒素对肝癌细胞凋亡的影响,为进一步研究富马毒素诱导凋亡的机制打下基础。方法利用PI标记的流式细胞术测定不同浓度下富马毒素对体外培养肝癌细胞凋亡率的影响。结果在1.25nmol/ml的富马毒素作用下凋亡率与空白没有差异,在2.5～40nmol/mlFB1的浓度范围内出现了明显的凋亡,随着富马毒素浓度的增加,体外培养的肝细胞凋亡率增加,且凋亡率在15nmol/ml达到高峰。结论富马毒素可导致肝癌细胞凋亡,随着浓度的递增,其凋亡率也随之递增。     

家族性ALS的临床特征及基因分析

目的探讨肌萎缩侧索硬化症(ALS)家系的临床特点及SOD1基因突变规律。方法详细分析一个FALS大家系的临床特征、肌电图改变、遗传方式,用PCR-SSCP法检测SOD1基因的突变。结果该家系有6代、237人,其中13人患病,8人死于ALS,具典型ALS症状,但起病前有较长一段时间肌肉纤颤期。PCR-SSCP法检测SOD1基因未发现突变,为非SOD1基因突变的ALS家系。结论(1)对于家族性肌跳的患者,宜动态观察其肌电图的改变,注重临床随访;(2)该家系可能存在一个非SOD1基因的、新的FALS致病基因。     

Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death

OBJECTIVES: The purpose of this study was to determine the clinical and biophysical characteristics of a novel SCN5A mutation. BACKGROUND: Brugada syndrome and isolated cardiac conduction defect have been linked to SCN5A mutations. METHODS: Eleven members of a western European family underwent electrophysiologic investigations and mutation analysis of the SCN5A gene. Wild-type and mutant SCN5A channels were expressed in HEK293 cells, and whole cell currents were studied using patch clamp procedures. RESULTS: A novel mutation, R376H, in the first pore segment of SCN5A variably causes Brugada syndrome and/or conduction disease in a single family. Biophysical analysis demonstrated a significant current reduction for the mutant, a pathophysiologic profile consistent with Brugada syndrome and isolated cardiac conduction defect. Among 11 family members, 9 were carriers of the mutation. The proband's initial presentation was a saddleback Brugada ECG, atrial flutter, and diffuse conduction disturbances. He had no inducible ventricular arrhythmias but experienced sudden cardiac death. His brother was affected by atrial flutter and had a clear conduction disorder, but he did not display baseline or evocable ECG signs of Brugada syndrome. He received an implantable cardioverter-defibrillator that delivered one appropriate shock after 1 year of follow-up. The phenotype in the family members was highly variable and ranged from noninducible and inducible asymptomatic carriers of the mutations to isolated conduction disease and to symptomatic Brugada syndrome. CONCLUSIONS: We describe the functional characterization of a novel SCN5A pore mutation, R376H, with variable clinical expression in the same family. Differentiating between electrophysiologic entities (Brugada syndrome-isolated cardiac conduction defect) is more challenging. Recognition of factors modifying the clinical presentation may be important for clinical decision making.     

O-GlcNAc糖基转移酶在原核和真核细胞中的表达和提纯

目的 :本文为进一步研究蛋白 O- Glc NAc糖基化修饰提供重要资源。方法 :为了探索制备纯化具有生物学活性的重组 OGT的有效方法 ,本文用大肠杆菌和 Hi5昆虫细胞表达并纯化具有活性的重组 OGT。携带人 OGTc DNA的 PET32 a质粒在大肠杆菌中表达出带有 1个 S- Tag的重组人 OGT融合蛋白 ,然后用与 S-蛋白质偶联的琼脂糖凝胶颗粒从细菌裂解液中亲和纯化 OGT融合蛋白。结果 :其纯化的 OGT在电泳中显现单一条带并具有生物活性 ,但其活性在洗脱后丧失。在 Hi5昆虫细胞中表达的鼠肝 OGT带有一 His6 tag,经镍离子螯合柱纯化后 ,其比活性达到 0 .88nmol· min- 1 · mg- 1 OGT。结论 :在这两个表达系统中制备重组 OGT各有利弊。     

非诺贝特对培养的兔脂肪细胞表达凝血和纤溶因子的影响

目的探讨非诺贝特对培养的兔脂肪细胞表达组织因子(TF)和纤溶酶原激活物抑制剂1(PAI-1)的影响.方法取正常兔脂肪组织分离培养脂肪细胞,以不同浓度(分别为0,1,10和100μmol/L)非诺贝特孵育兔脂肪细胞24 h后收集细胞.RT-PCR测定脂肪细胞TF和PAI-1 mRNA表达.用ELISA方法测定TF和PAI-1浓度.结果不同浓度非诺贝特均可抑制兔脂肪组织细胞TF和PAI-1的表达和蛋白产生,其抑制作用呈浓度依赖性增强.在非诺贝特10μmol/L培养时兔脂肪细胞TF和PAI-1 mRNA分别为(0.504±0.016)和(1.500±0.096),明显低于对照[分别为(0.579±0.018)和(1.607±0.063),均P＜0.01].在非诺贝特100μmol/L培养时兔脂肪细胞TF和PAI-1 mRNA分别为(0.451±0.023)和(1.269±0.084),与对照比显著降低(均P＜0.001).结论非诺贝特能抑制兔脂肪细胞TF和PAI-1 mRNA和蛋白的表达,提示非诺贝特可能具有独立于降脂作用外的抗血栓作用.     

聚对苯撑乙炔的合成及光谱性能-共轭主链被间位苯环阻隔

报道了一种阻隔型聚对幕撑乙炔((PPE)的合成与电致发光特性，合成的模型小分子证明，在聚对苯撑乙炔(PPV)主链引入间位幕环，可阻隔PPV的有效共轭长度，改变其发光颜色，研究了电致发光暑件ITO／m-PPE／Al的电致发光特性。     

高半胱氨酸促THP-1巨噬细胞表达单核细胞趋化蛋白-1和辛伐他汀的调节作用

目的 :研究高半胱氨酸 (Hcy)对人单核细胞系 (THP 1)分化而来的巨噬细胞 (THP 1巨噬细胞 )表达单核细胞趋化蛋白 1(MCP 1)的影响及辛伐他汀可能存在的调节作用。方法 :在培养的THP 1中加入佛波脂(PMA) ,使终浓度为 2 0ng/ml,培养 4 8h ,细胞贴壁呈巨噬细胞样分化。他汀组和Hcy组分别加入含有辛伐他汀(10 μmol/L ,5 0 μmol/L)或不含辛伐他汀完全培养基 37℃培养 2 4h ,再加入含DL Hcy(0 1mmol/L)完全培养基 ,对照组只加完全培养基 ,培养 2～ 2 4h ,上清离心 5 0 0g ,10min ,- 2 0℃保存。用ELISA法检测上清中MCP 1蛋白的量。每孔重复 3次。结果 :与对照组比较 ,加入 0 1mmol/LHcy可使THP 1巨噬MCP 1蛋白表达升高 ,4h后显著升高 (P <0 0 5 ) ,6h达高峰 (P <0 0 1) ,12h后逐渐下降 (P <0 0 5 ) ,分别为对照组的 2 9倍、5 8倍和 2 6倍 ,2 4h与对照组无显著差异。 10 μmol/L、5 0 μmol/L辛伐他汀分别使与Hcy共孵育 6h(高峰时间 )MCP 1蛋白量下降至Hcy组的 5 7 11%、2 3 6 4 %。结论 :病理浓度的Hcy(0 1mmol/L)可时间依赖性促进THP 1巨噬细胞表达MCP 1蛋白 ,该作用可被辛伐他汀下调。     

丝裂素活化蛋白激酶磷酸酶-1对血管平滑肌细胞增殖的影响及其机制

目的 研究丝裂素活化蛋白激酶磷酸酶-1(MKP1)对血管平滑肌细胞增殖的影响及机制。方法 转染MKP1质粒72h后，收集培养的血管平滑肌细胞(VSMC)，利用P^42／P^44磷酸化抗MAPK抗体通过免疫印迹法测定MAPK活性，用流试细胞仪测定细胞周期、细胞周期素和P27蛋白的表达。结果 转染MKP1质粒后，MAPK活性明显下降，VSMC阻滞于G0-G1期，同时抑制了细胞周期素D、E的表达，P27蛋白表达却明显增加。结论 MKP1抑制VSMC增殖可能是通过降低MAPK活性，抑制细胞周期素表达和增加P27蛋白表达途径实现的。     

The severity of airways obstruction as a determinant of treatment response in COPD

Guidelines recommend that patients with COPD are stratified arbitrarily by baseline severity (FEV₁) to decide when to initiate combination treatment with a long-acting β₂-agonist and an inhaled corticosteroid. Assessment of baseline FEV₁ as a continuous variable may provide a more reliable prediction of treatment effects. Patients from a 1-year, parallel-group, randomized controlled trial comparing 50 μg salmeterol (Sal), 500 μg fluticasone propionate (FP), the combination (Sal/FP) and placebo, (bid), were categorized post hoc into FEV₁ <50% and FEV₁ ≥50% predicted subgroups (n=949/513 respectively). Treatment effects on clinical outcomes – lung function, exacerbations, health status, diary card symptoms, and adverse events – were investigated. Treatment responses based on a pre-specified analysis explored treatment differences by severity as a continuous variable. Lung function improved with active treatment irrespective of FEV₁; Sal/FP had greatest effect. This improvement appeared additive in milder disease; synergistic in severe disease. Active therapy significantly reduced exacerbation rate in patients with FEV₁ <50% predicted, not in milder disease. Health status and breathlessness improved with Sal/FP irrespective of baseline FEV₁; adverse events were similar across subgroups. The spirometric response to Sal/FP varied with baseline FEV₁, and clinical benefits were not restricted to patients with severe disease. These data have implications for COPD management decisions, suggesting that arbitrary stratifications of baseline severity are not necessarily indicative of treatment efficacy and that the benefits of assessing baseline severity as a continuous variable should be assessed in future trials.     

微泵输注氟尿嘧啶结合生长抑素治疗壶腹部周围癌

目的 :生长抑素 (SS)结合氟尿嘧啶 (5 - Fu)治疗晚期壶腹部周围癌的疗效评价。方法 :2 8例晚期壶腹部周围癌患者均采用静脉插管及随身携带微型输注泵 ,SS/ 5 - Fu持续静脉滴注 (civ法 )。结果 :经 2周期治疗后 ,临床症状缓解 (DRSI)为 89.3% (2 5 / 2 8) ;肿瘤完全缓解 (CR)占 3.7% ,部分缓解 (PR) ,占 2 8.6 % ,稳定 (NC)占 4 6 .4 % ,有效率为 32 .1%。结论 :SS/ 5 - Fu化学治疗效果稳定 ,毒副作用轻微 ,是治疗晚期壶腹部周围癌的有效手段之一。